Reviva Pharmaceuticals (RVPH) Competitors $0.78 +0.07 (+10.35%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.79 +0.00 (+0.46%) As of 04/17/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. PRQR, RAPT, GLSI, FDMT, NKTX, KRRO, LRMR, ADCT, THTX, and CGENShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include ProQR Therapeutics (PRQR), RAPT Therapeutics (RAPT), Greenwich LifeSciences (GLSI), 4D Molecular Therapeutics (FDMT), Nkarta (NKTX), Korro Bio (KRRO), Larimar Therapeutics (LRMR), ADC Therapeutics (ADCT), Theratechnologies (THTX), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. ProQR Therapeutics RAPT Therapeutics Greenwich LifeSciences 4D Molecular Therapeutics Nkarta Korro Bio Larimar Therapeutics ADC Therapeutics Theratechnologies Compugen Reviva Pharmaceuticals (NASDAQ:RVPH) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Which has stronger valuation and earnings, RVPH or PRQR? ProQR Therapeutics has higher revenue and earnings than Reviva Pharmaceuticals. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$39.26M-$0.91-0.86ProQR Therapeutics$18.91M6.34-$30.43M-$0.34-3.35 Is RVPH or PRQR more profitable? Reviva Pharmaceuticals has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Reviva Pharmaceuticals' return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -252.53% ProQR Therapeutics -134.31%-71.58%-19.70% Does the MarketBeat Community believe in RVPH or PRQR? ProQR Therapeutics received 308 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 90.32% of users gave Reviva Pharmaceuticals an outperform vote while only 61.99% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformReviva PharmaceuticalsOutperform Votes2890.32% Underperform Votes39.68%ProQR TherapeuticsOutperform Votes33661.99% Underperform Votes20638.01% Which has more risk and volatility, RVPH or PRQR? Reviva Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Does the media prefer RVPH or PRQR? In the previous week, ProQR Therapeutics had 9 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 9 mentions for ProQR Therapeutics and 0 mentions for Reviva Pharmaceuticals. ProQR Therapeutics' average media sentiment score of 0.82 beat Reviva Pharmaceuticals' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Reviva Pharmaceuticals Neutral ProQR Therapeutics Positive Do insiders & institutionals believe in RVPH or PRQR? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend RVPH or PRQR? Reviva Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 1,178.12%. ProQR Therapeutics has a consensus price target of $9.50, indicating a potential upside of 733.33%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryReviva Pharmaceuticals beats ProQR Therapeutics on 9 of the 17 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.57M$6.44B$5.30B$7.35BDividend YieldN/A3.20%5.45%4.30%P/E Ratio-0.706.8921.8617.81Price / SalesN/A230.51380.6697.70Price / CashN/A65.6738.2634.64Price / Book3.915.936.453.98Net Income-$39.26M$142.99M$3.22B$247.81M1 Month Performance-26.88%-13.56%-9.75%-7.92%1 Year Performance-74.09%-8.89%11.50%1.52% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals2.2846 of 5 stars$0.78+10.4%$10.00+1,178.1%-74.1%$36.57MN/A-0.705Upcoming EarningsPRQRProQR Therapeutics2.3804 of 5 stars$1.18+5.4%$9.50+705.1%-38.7%$124.15M$18.91M-3.69180Short Interest ↓News CoverageRAPTRAPT Therapeutics3.6147 of 5 stars$0.93+7.2%$4.00+332.0%-90.0%$122.24M$1.53M-0.3380Short Interest ↑News CoverageGLSIGreenwich LifeSciences1.5221 of 5 stars$9.28-5.9%$38.00+309.5%-30.6%$121.99MN/A-11.603Earnings ReportUpcoming EarningsPositive NewsGap UpHigh Trading VolumeFDMT4D Molecular Therapeutics2.6547 of 5 stars$2.78+5.7%$26.71+860.9%-87.7%$121.77M$37,000.00-0.98120Analyst RevisionNews CoveragePositive NewsGap DownNKTXNkarta2.857 of 5 stars$1.70+7.9%$14.86+773.9%-76.8%$120.63MN/A-0.90140Short Interest ↓Positive NewsKRROKorro Bio1.3716 of 5 stars$12.84-0.5%$136.33+961.8%-79.2%$120.56M$2.27M-1.3770Analyst ForecastNews CoveragePositive NewsGap UpLRMRLarimar Therapeutics3.2153 of 5 stars$1.87+3.3%$19.63+949.5%-70.1%$119.73MN/A-1.6330Positive NewsADCTADC Therapeutics2.1762 of 5 stars$1.21-1.2%$7.75+543.2%-74.5%$119.40M$70.84M-0.50310THTXTheratechnologiesN/A$2.57+32.5%N/A+92.4%$118.17M$85.87M-25.70140Analyst RevisionNews CoverageHigh Trading VolumeCGENCompugen1.2717 of 5 stars$1.31+4.0%$4.00+205.3%-21.8%$116.90M$27.86M65.5070Gap Up Related Companies and Tools Related Companies PRQR Alternatives RAPT Alternatives GLSI Alternatives FDMT Alternatives NKTX Alternatives KRRO Alternatives LRMR Alternatives ADCT Alternatives THTX Alternatives CGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RVPH Stock Free RVPH Stock Alerts